Zerit Xr Patent Expiration

Zerit Xr is a drug owned by Bristol Myers Squibb Co. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 18, 2023. Details of Zerit Xr's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7135465 Sustained release beadlets containing stavudine
Feb, 2023

(1 year, 4 months ago)

Expired
US7135465

(Pediatric)

Sustained release beadlets containing stavudine
Aug, 2023

(10 months ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Zerit Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zerit Xr's family patents as well as insights into ongoing legal events on those patents.

Zerit Xr's family patents

Zerit Xr has patent protection in a total of 24 countries. It's US patent count contributes only to 11.5% of its total global patent coverage. 21 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Zerit Xr.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Zerit Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 18, 2023 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Zerit Xr Generics:

Stavudine is the generic name for the brand Zerit Xr. 5 different companies have already filed for the generic of Zerit Xr, with Aurobindo Pharma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Zerit Xr's generic





About Zerit Xr

Zerit Xr is a drug owned by Bristol Myers Squibb Co. It is used for managing HIV-1 infection. Zerit Xr uses Stavudine as an active ingredient. Zerit Xr was launched by Bristol Myers Squibb in 2002.

Market Authorisation Date:

Zerit Xr was approved by FDA for market use on 31 December, 2002.

Active Ingredient:

Zerit Xr uses Stavudine as the active ingredient. Check out other Drugs and Companies using Stavudine ingredient

Treatment:

Zerit Xr is used for managing HIV-1 infection.

Dosage:

Zerit Xr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
50MG CAPSULE, EXTENDED RELEASE Discontinued ORAL
75MG CAPSULE, EXTENDED RELEASE Discontinued ORAL
37.5MG CAPSULE, EXTENDED RELEASE Discontinued ORAL
100MG CAPSULE, EXTENDED RELEASE Discontinued ORAL